Phase III study of CYT 387 in patients with myelofibrosis

Trial Profile

Phase III study of CYT 387 in patients with myelofibrosis

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2011

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors YM BioSciences
  • Most Recent Events

    • 03 Jun 2011 Planned initiation date changed from 1 Jan 2012 to 1 Jun 2012.
    • 11 Feb 2011 New trial record
    • 10 Feb 2011 YM Biosciences hopes to commence this pivotal trial in Q1 2012, according to a YM BioSciences media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top